Drug details

Ojjaara (momelotinib tablets)

type of Antineoplastics JAK Inhibitors

Ojjaara (momelotinib) is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

This drug may have the following side effects:

• nausea,
• itching,
• rash,
• diarrhea,
• fever,
• dizziness,
• fatigue,
• cough,
• bleeding,
• abdominal pain,
• numbness and tingling,
• elevated liver enzymes,
• viral infection,
• low blood platelets,
• bacterial infection,
• kidney and urinary tract infection (UTI),
• irregular heartbeats (arrhythmias), and
• low white blood cells (neutropenia).

The following drugs are related to Ojjaara, either as a replacement or used together:

• Inrebic (fedratinib capsules)
• Jakafi (ruxolitinib)
• Vonjo (pacritinib capsules)